ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Price, Quote, News and Overview
NYSEARCA:ATNM - NYSE Arca - US00507W2061 - Common Stock - Currency: USD
ATNM Quote, Performance and Key Statistics
NYSEARCA:ATNM (2/19/2025, 3:49:59 PM)
1.18
-0.08 (-6.35%)
The current stock price of ATNM is 1.18 USD. In the past month the price decreased by -10%. In the past year, price decreased by -81.63%.
ATNM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.48 | 348.44B | ||
| AMGN | AMGEN INC | 14.88 | 158.34B | ||
| GILD | GILEAD SCIENCES INC | 23.39 | 134.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1624.62 | 121.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.08 | 75.25B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.29B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.53B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 22.69B | ||
| BIIB | BIOGEN INC | 8.29 | 19.90B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.66 | 16.94B |
Related stock screener links
About ATNM
Company Profile
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The firm focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The firm holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Company Info
ACTINIUM PHARMACEUTICALS INC
100 Park Ave., 23Rd Floor
New York City NEW YORK 10016 US
CEO: Sandesh Seth
Employees: 49
Company Website: https://www.actiniumpharma.com/
Investor Relations: https://ir.actiniumpharma.com/
Phone: 16466773870
ATNM FAQ
What is the stock price of ATNM?
The current stock price of ATNM is 1.18 USD.
What is the symbol for ACTINIUM PHARMACEUTICALS INC stock?
The exchange symbol of ACTINIUM PHARMACEUTICALS INC is ATNM and it is listed on the NYSE Arca exchange.
On which exchange is ATNM stock listed?
ATNM stock is listed on the NYSE Arca exchange.
Is ATNM a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ATNM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ATNM.
Does ATNM stock pay dividends?
ATNM does not pay a dividend.
When does ATNM stock report earnings?
ATNM will report earnings on 2025-03-14, after the market close.
What is the Price/Earnings (PE) ratio of ATNM?
ATNM does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
What is the Short Interest ratio of ATNM stock?
The outstanding short interest for ATNM is 6.6% of its float.
ATNM Technical Analysis
ATNM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNM. The financial health of ATNM is average, but there are quite some concerns on its profitability.
ATNM Financial Highlights
Over the last trailing twelve months ATNM reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS decreased by 27.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.83% | ||
| ROE | -107.08% | ||
| Debt/Equity | 0 |
ATNM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ATNM. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 22.42% and a revenue growth 5.08% for ATNM